New pharma–AI partnerships: Novo Nordisk–Anthropic, Lilly–Twist, Boehringer Ingelheim–Envisagenics
Novo Nordisk has teamed up with Anthropic, Twist Bioscience with Lilly's TuneLab programme, and Boehringer Ingelheim with Envisagenics (in a deal worth up to $1bn) on AI-based drug discovery. Anthropic is also setting up a biology lab; the news arrived on 21–22 September.
Who is affected and how
- pharmaceuticals
- Contracts with AI companies are multiplying quickly, so it is worth setting terms for target identification and data sharing proactively.
Sources
- Novo Nordisk Partners with Anthropic to Bring AI Deeper into Drug Discoveryyahoo finance · Sep 21, 2026
- Novo Nordisk and Anthropic Announce Collaboration to Advance Drug Discovery With Claudebiobuzz · Sep 21, 2026
- Anthropic sets up biology lab as it ramps AI drug programtucson.com · Sep 21, 2026
- Anthropic is setting up a biology lab where Claude guides robots through drug experimentsthe-decoder.com · Sep 22, 2026
- Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Dealstockstotrade · Sep 24, 2026
- Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics - BioSpacebiospace.com · Sep 22, 2026 · magyar
- Hanx Bio licenses XtalPi AI drug discovery platform for biologics R&Dallsci · Sep 21, 2026
- Virtual Biotech "Employs" 37,000 AI Agents for End-to-End Drug Developmenttechnology networks · Sep 21, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.